Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, National, Multicenter, Observational Real-World Study of Acalabrutinib in Chinese Patients With MCL/CLL/SLL(RESA)

NCT06767891 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06767891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06767891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, National, Multicenter, Observational Real-World Study of Acalabrutinib in Chinese Patients With MCL/CLL/SLL(RESA)
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
July 2, 2024
Completion date
November 30, 2029
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), mantle cell lymphoma (mcl)